CATALYSTStock Titan • 17h ago
Blood-sugar drops after weight-loss surgery have no FDA-approved treatment. Vogenx starts a trial.Stock Titan report covering Vogenx Inc (VOGX) market action, institutional positioning, and fundamental catalysts.
Why VOGX Stock advanced +1.66% Today — RQD Quant Desk Flash
$20.25 +1.66% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $20.27
Vogenx Inc (VOGX) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $300.8M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on VOGX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is VOGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Vogenx Inc (NASDAQ: VOGX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $20.25 (+1.66% 1D, market cap $300.8M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does VOGX compare to BNTC and IRD in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VOGX carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, BNTC (Benitec Biopharma Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $304.9M) and IRD (Opus Genetics Inc.) posts a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $305.3M). Among the 5-stock peer group, VOGX leads on earnings multiple (N/A) while BNTC leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for VOGX?
▼
Per VOGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001903784), Vogenx Inc generated $0 in revenue, $0 in net income, and $0 in free cash flow against $681.2K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $20.27 (+0.11%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.2% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-5.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VOGX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (45/100 Composite)
🔍 WHY VOGX SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (29% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (22% of score)
SEC XBRL FY 2025 (10-K): 0.2% FCF Margin ($8.4M FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$16.76+11.9% Next Q
37
Q2 (-2Q)Grade D$18.75+2.2% Next Q
40
Q3 (-1Q)Grade D$19.16+5.7% Next Q
42
CurrentGrade D$20.25-6.3% Hist 90D α
45
Trajectory: E (37) → D (45)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a VOGX Turnaround Squeeze
While VOGX currently carries a cautious 45/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($24.28) and Max Pain ($21.26) forces dealer call-delta covering toward $40.33.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $VOGX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “VOGX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why VOGX Stock advanced +1.66% Today — RQD Quant Desk Flash
Vogenx Inc (VOGX) advanced +1.66% to $20.25, trading at 29% of its 52-week range ($12.95 – $38.41). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 29% of its 52-week range ($12.95 – $38.41) with RSI-14 at 52.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $20.25 (no active unusual options sweep snapshot on file).
- ▸Primary SEC / Cross-Feed Trigger: VOGX Exhibits 6.00x True Net Liquidity Elasticity as Fed-TGA-RRP Prints $5,746B
Live VOGX Headlines & Catalysts
MARKET WIREBenzinga • 20h ago
12 Health Care Stocks Moving In Thursday's Pre-Market SessionBenzinga report covering Vogenx Inc (VOGX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETraders Union • 23h ago
Vogenx Inc Stock Price Today | VOGX Live Chart & NewsTraders Union report covering Vogenx Inc (VOGX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETraders Union • 1d ago
Live Vogenx Inc (VOGX) Technical AnalysisTraders Union report covering Vogenx Inc (VOGX) market action, institutional positioning, and fundamental catalysts.
RISK WATCHBenzinga • 12d ago
Why QuantumScape Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving PremarketQuantumScape rises 9.1% after narrower loss and new solid-state battery production plans; SHFS leads gainers while POM and others fall premarket.
MARKET WIREBenzinga • 12d ago
12 Health Care Stocks Moving In Wednesday's After-Market SessionGainers Tempest Therapeutics (NASDAQ:TPST) stock rose 8.9% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $10.1 million. Tenax Therapeutics (NASDAQ:TENX)
MARKET WIREYahoo • 18d ago
Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric HypoglycemiaThere are currently no therapeutics approved by the U. Food and Drug Administration for the treatment of PBH.
CATALYSTBenzinga • 18d ago
Vogenx Initiates EMERGE, Phase 2b Clinical Trial Evaluating Mizagliflozin For Treatment Of Post-Bariatric HypoglycemiaRandomized, double-blind, placebo-controlled trial will evaluate two doses of the first-in-class, minimally absorbed SGLT1 inhibitor in patients with recurrent hypoglycemia following bariatric surgeryRALEIGH, NC /
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VOGX)
- ✓Walkthrough of VOGX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
VOGX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +55.77%▲ ASCENDING CHANNEL
2026-11-03O $19.92H $20.25L $19.92C $20.25VOL 45.1K
RES: $43.89SUP: $15.24SMA50: $24.28SMA200: $23.70
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
VOGX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on VOGX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for VOGX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VOGX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VOGX)
Health Care Rank #368 of 1016
⚔️ BNTC vs VOGX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (VOGX vs. BNTC, IRD, PRLD, ENTA)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Vogenx Inc (VOGX) ranks #368 by composite RQD confidence (45/100, grade D) and #519 by equity capitalization ($300.8M). Within this direct 5-issuer industry benchmark cohort, VOGX leads on earnings valuation at N/A trailing P/E, while BNTC leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. VOGX currently leads its immediate peer cohort in composite quantitative strength at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| VOGX
ACTIVE
Vogenx Inc | D | 45/100 | — | — | — | +1.66% | $300.8M | Benchmark Subject |
| BNTC Benitec Biopharma Inc. | E | 30/100 | — | — | -35.0% | -1.02% | $304.9M | /bntc-vs-vogx → |
| IRD Opus Genetics Inc. | E | 23/100 | — | — | -35.0% | +0.55% | $305.3M | /ird-vs-vogx → |
| PRLD Prelude Therapeutics Incorporated | E | 33/100 | — | — | -35.0% | -5.37% | $309.6M | /prld-vs-vogx → |
| ENTA Enanta Pharmaceuticals Inc. | E | 20/100 | — | — | -35.0% | -3.95% | $311.9M | /enta-vs-vogx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001903784In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vogenx Inc (VOGX) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, VOGX closed FY2025 with $681.2K in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $0 | — | — | $681.2K | — |
3. VOGX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs VOGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Vogenx Inc (NASDAQ: VOGX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $20.25 (+1.66% 1D, market cap $300.8M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.
How does VOGX compare to BNTC and IRD in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VOGX carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, BNTC (Benitec Biopharma Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $304.9M) and IRD (Opus Genetics Inc.) posts a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $305.3M). Among the 5-stock peer group, VOGX leads on earnings multiple (N/A) while BNTC leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for VOGX?
Per VOGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001903784), Vogenx Inc generated $0 in revenue, $0 in net income, and $0 in free cash flow against $681.2K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is VOGX trading relative to its 50-day, 200-day, and 52-week technical levels?
VOGX last traded at $20.25 (+1.66% on volume of 45,089 shares), positioning the stock -16.60% below its 50-day simple moving average ($24.28) and -14.56% below its 200-day simple moving average ($23.70). Across its 52-week range of $12.95 to $38.41, VOGX sits at the 28.7% percentile with a 14-day RSI of 52.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($17.72 to $22.78).
VOGX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is VOGX stock moving today?
Why VOGX Stock advanced +1.66% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 45/100 (D)
✓ STAGE-C NUMBER FIREWALL VERIFIED
VOGX — Vogenx Inc: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:16:49Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, VOGX scores 45 out of 100, earning a D grade and the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 10 of 20 (ROIC 0%; FCF yield 0%); Whale 13F Flow at 5 of 20 (institutional accumulation and options positioning); Insider Conviction at 9 of 20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 8 of 20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 13 of 20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5).
For a prospective investor, the weakest pillars are institutional flow, insider conviction, and macro fit, while the balance sheet is the relative strength. The 0% ROIC and 0% FCF yield indicate the cash-generation engine is not visible in the source data, so the investment case rests on factors other than current earnings power. The Altman Z of 2.5 and Piotroski F of 6/9 provide some forensic comfort, but they do not offset the absence of demonstrated returns. Any upside would depend on a sentiment or catalyst-driven re-rating rather than on fundamentals currently reflected in the data.
Recent Catalysts & News Wire Analysis
Per the recent news feed, the lead item (Stock Titan, flagged as a green CATALYST) reports that Vogenx starts a trial addressing blood-sugar drops after weight-loss surgery, for which no FDA-approved treatment exists. Three additional items (Benzinga, Traders Union twice) are yellow market-wire entries: one lists VOGX among health care stocks moving in pre-market trading, and two are generic price and technical-analysis pages.
Per the Butterfly Supply-Chain Graph, a proprietary LIQUIDITY_TAILWIND signal is BEARISH with severity 94 and a Macro Tailwind Score of 18/100. The signal cites True Net Liquidity contracting -0.64% over four weeks to $5,746B, a 2 bps widening in ICE BofA High-Yield OAS, and a 6.1 z-score macro divergence. It also cites VOGX's Net Liquidity Elasticity of 6.00x Beta (r=+0.30). Key risk watch items are this macro headwind and the absence of demonstrated earnings.
Open Questions
- What are VOGX's revenue, operating income, and net income figures in dollars beyond the reported $0.0M, and what drives the 0% margins?
- What is the company's debt in dollar terms, given that the FY 2025 debt field is N/A despite a Debt/Equity of 0.5?
- What is the status and timeline of the post-surgery blood-sugar trial referenced in the lead news item, and what is its stage or funding?
- Who are the institutional and insider holders, and what are the 13F and Form 4 positions behind the 5/20 whale-flow and 9/20 insider pillars?
- What are the TTM earnings, forward estimates, and any analyst coverage that would allow valuation to be assessed?
VOGX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Vogenx Inc (VOGX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Stock Titan • 17h ago
Blood-sugar drops after weight-loss surgery have no FDA-approved treatment. Vogenx starts a trial. Stock Titan report covering Vogenx Inc (VOGX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 20h ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session Benzinga report covering Vogenx Inc (VOGX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Traders Union • 23h ago
Vogenx Inc Stock Price Today | VOGX Live Chart & News Traders Union report covering Vogenx Inc (VOGX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Traders Union • 1d ago
Live Vogenx Inc (VOGX) Technical Analysis Traders Union report covering Vogenx Inc (VOGX) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Benzinga • 12d ago
Why QuantumScape Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket QuantumScape rises 9.1% after narrower loss and new solid-state battery production plans; SHFS leads gainers while POM and others fall premarket.
🟡 MARKET WIRE Benzinga • 12d ago
12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Tempest Therapeutics (NASDAQ:TPST) stock rose 8.9% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $10.1 million. Tenax Therapeutics (NASDAQ:TENX)
🟡 MARKET WIRE Yahoo • 18d ago
Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia There are currently no therapeutics approved by the U. Food and Drug Administration for the treatment of PBH.
🟢 CATALYST Benzinga • 18d ago
Vogenx Initiates EMERGE, Phase 2b Clinical Trial Evaluating Mizagliflozin For Treatment Of Post-Bariatric Hypoglycemia Randomized, double-blind, placebo-controlled trial will evaluate two doses of the first-in-class, minimally absorbed SGLT1 inhibitor in patients with recurrent hypoglycemia following bariatric surgeryRALEIGH, NC /
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
VOGX Bull vs. Bear Conversation Board — What's Your Call at $20.25?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VOGX 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $17.53 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is VOGX (D • RQD 45/100) a Buy at $19.92?
Welcome to the VOGX (Vogenx Inc) Roar Pit. Current RQD Composite is 45/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $16.53 (-17.0%)
Spot @ $19.92 Pump the brakes on VOGX — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on VOGX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Vogenx Inc expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH
🎯 Target: $23.90 (+20.0%)
Spot @ $19.92 VOGX cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on VOGX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $19.92 (52-wk range $12.95 - $38.41), any beat on forward guidance forces shorts and underweight funds to chase.